β-thalassemia intermedia in Northern Iraq: A single center experience

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Al Allawi, Nasir A S ^a   Jalal, Sana D ^b   Mohammad, Ameen M ^a   Omer, Sharaza Q ^c   Markous, Raji S D ^d  

^a UNIVERSITY OF DUHOK   (Iraq)

^b UNIVERSITY OF SULAIMANI   (Iraq)

^c Department of Hematology   (Iraq)

^d Thalassemia Care Center   (Iraq)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; DEFEROXAMINE; DEFEROXAMINE MESYLATE; HEMOGLOBIN ALPHA CHAIN; HYDROXYUREA;

ADOLESCENT; ADULT; ALLELE; ARTICLE; CHILD; CODON; DIABETES MELLITUS; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HEART FAILURE; HUMAN; HYPOTHYROIDISM; INHERITANCE; IRAQ; IRON CHELATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PHENOTYPE; PRESCHOOL CHILD; PULMONARY HYPERTENSION; SCHOOL CHILD; SPLENECTOMY; THALASSEMIA INTERMEDIA; VEIN THROMBOSIS; BETA THALASSEMIA; GENETICS; HAPLOTYPE; MUTATION; PATHOLOGY;

ADOLESCENT; ADULT; ALPHA-GLOBINS; BETA-THALASSEMIA; CHILD; CHILD, PRESCHOOL; FEMALE; HAPLOTYPES; HUMANS; IRAQ; MALE; MIDDLE AGED; MUTATION; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 84897893685     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/262853     Document Type: Article

References (36)

1. Weatherall D. J., Clegg J. B., The Thalassaemia Syndromes 2001 4th Oxford, UK Blackwell scientific Publications
2. Musallam K. M., Taher A. T., Rachmilewtiz E. A., β -thalassemia intermedia: a clinical perspective. Cold Spring Harbor Perspectives in Medicine 2012 2 7 013482 10.1101/cshperspect.a013482
3. Galanello R., Cao A., Relationship between genotype and phenotype: thalassemia intermedia. Annals of the New York Academy of Sciences 1998 850 325 333 2-s2.0-0031872838
4. Al-Allawi N. A. S., Jubrael J. M. S., Hughson M., Molecular characterization of β -thalassemia in the Dohuk region of Iraq. Hemoglobin 2006 30 4 479 486 2-s2.0-33748929647 10.1080/03630260600868097 (Pubitemid 44435289)
5. Al-Allawi N. A., Hassan K. M. A., Sheikha A. K., Nerweiy F. F., Dawood R. S., Jubrael J., β thalassemia mutations among transfusion dependent thalassemia major patients in Northern Iraq. Molecular Biology International 2010 2010 4 479282 10.4061/2010/479282
6. Al-Allawi N. A., Mousawi B. S., Badi A. A., Jalal S. D., The spectrum of β -thalassemia mutations in Baghdad. Hemoglobin 2013 37 5 444 453
7. Qatanani M., Taher A., Koussa S., Naaman R., Fisher C., Rugless M., Old J., Zahed L., β -thalassaemia intermedia in Lebanon. European Journal of Haematology 2000 64 4 237 244 2-s2.0-0034112971 10.1034/j.1600-0609.2000.90087.x (Pubitemid 30186781)
8. Old J., Traeger-Synodinos J., Galanello R., Petrou M., Angastiniotis M., Prevention of thalassaemia and other haemoglobin disorders. Thalassaemia International Federation Publications 2005 2 113 116
9. Oron-Karni V., Filon D., Oppenheim A., Rund D., Rapid detection of common mediterranean α -globin deletions/rearrangements using PCR. American Journal of Hematology 1998 58 4 306 310 (Pubitemid 28346018)
10. Barst R. J., McGoon M., Torbicki A., Sitbon O., Krowka M. J., Olschewski H., Gaine S., Diagnosis and differential assessment of pulmonary arterial hypertension. Journal of the American College of Cardiology 2004 43 12 S40 S47 2-s2.0-2942603006 10.1016/j.jacc.2004.02.032 (Pubitemid 38759716)
11. Kleber F. X., Niemoller L., Doering W., Impact of converting enzyme inhibition on progression of chronic heart failure: results of the Munich Mild Heart Failure Trial. British Heart Journal 1992 67 4 289 296 2-s2.0-0026576983
12. Baskin H. J., Cobin R. H., Duick D. S., American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocrine Practice 2002 8 6 457 469
13. Chen W., Zhang X., Shang X., Cai R., Li L., Zhou T., Sun M., Xiong F., Xu X., The molecular basis of β -thalassemia intermedia in southern China: genotypic heterogeneity and phenotypic diversity. BMC Medical Genetics 2010 11 1, article 31 2-s2.0-77951934080 10.1186/1471-2350-11-31
14. Parkin C. G., Davidson J. A., Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European association for the study of Diabetes. Diabetes Care 2007 30 1 192 193 2-s2.0-33845993930 10.2337/dc06-1858 (Pubitemid 46052534)
15. Camaschella C., Mazza U., Roetto A., Gottardi E., Parziale A., Travi M., Fattore S., Bacchiega D., Fiorelli G., Cappellini M. D., Genetic interactions in thalassemia intermedia: analysis of β -mutations, α -genotype, γ -promoters, and β -LCR hypersensitive sites 2 and 4 in Italian patients. American Journal of Hematology 1995 48 2 82 87 2-s2.0-0028942051
16. Verma I. C., Kleanthous M., Saxena R., Fucharoen S., Winichagoon P., Raizuddin S., Khan S. N., Akbari M. T., Izadyar M., Kotea N., Old J. M., Ioannou P. A., Khan B., Multicenter study of the molecular basis of thalassemia intermedia in different ethnic populations. Hemoglobin 2007 31 4 439 452 2-s2.0-36249009162 10.1080/03630260701641245 (Pubitemid 350125634)
17. Neishabury M., Azarkeivan A., Oberkanins C., Esteghamat F., Amirizadeh N., Najmabadi H., Molecular mechanisms underlying thalassemia intermedia in Iran. Genetic Testing 2008 12 4 549 556 2-s2.0-57749096271 10.1089/gte.2008.0018
18. Thein S. L., Menzel S., Lathrop M., Garner C., Control of fetal hemoglobin: new insights emerging from genomics and clinical implications. Human molecular genetics 2009 18 2 R216 R223 2-s2.0-77949807007
19. Taher A. T., Musallam K. M., Cappellini M. D., Thalassemia intermedia: an update. Mediterranean Journal of Hematology and Infectious Diseases 2009 1 1 10.4084/MJHID.2009.004
20. Panigrahi I., Agarwal S., Pradhan M., Choudhry D. R., Choudhry V. P., Saxena R., Molecular characterization of thalassemia intermedia in Indians. Haematologica 2006 91 9 1279 1280 2-s2.0-33748786238 (Pubitemid 44408446)
21. Ho P. J., Hall G. W., Luo L. Y., Weatherall D. J., Thein S. L., Beta-thalassaemia intermedia: is it possible consistently to predict phenotype from genotype? British Journal of Haematology 1998 100 1 70 78 2-s2.0-0031972656 10.1046/j.1365-2141.1998.00519.x (Pubitemid 28051843)
22. Taher A. T., Musallam K. M., Karimi M., El-Beshlawy A., Belhoul K., Daar S., Saned M.-S., El-Chafic A.-H., Fasulo M. R., Cappellini M. D., Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the optimal care study. Blood 2010 115 10 1886 1892 2-s2.0-77950420281 10.1182/blood-2009-09-243154
23. Tyagi S., Kabra M., Tandon N., Saxena R., Pati H. P., Choudhry V. P., Clinico-haematological profile of thalssemia intermedia patients. International Journal of Human Genetics 2003 3 4 251 258
24. Karamifar H., Karimi M., Amirhakimi G. M., Badiei M., Endocrine function in thalassemia intermedia. International Journal of Biomedical Science 2006 2 3 236 240
25. Musallam K. M., Khoury B., Abi-Habib R., Bazzi L., Succar J., Halawi R., Hankir A., Koussa S., Taher A. T., Health-related quality of life in adults with transfusion-independent thalassaemia intermedia compared to regularly transfused thalassaemia major: new insights. European Journal of Haematology 2011 87 1 73 79 2-s2.0-79959520305 10.1111/j.1600-0609.2011.01623.x
26. Taher A. T., Musallam K. M., Karimi M., Cappellini M. D., Contemporary approaches to treatment of beta-thalassemia intermedia. Blood Reviews 2012 26 S24 S27
27. Taher A. T., Viprakasit V., Musallam K. M., Cappellini M. D., Treating Iron overload in patients with non-transfusion-dependent thalassemia. American Journal of Hematology 2013 88 5 409 415 10.1002/ajh.23405
28. Taher A. T., Porter J., Viprakasit V., Deferasirox effectively reduces iron overload in non-transfusion-dependent thalssemia (NTDT): 1-year extension results from the THALASSA study. Annals of Hematology 2013 93 11 1485 1493
29. Voskaridou E., Plata E., Douskou M., Papadakis M., Delaki E.-E., Christoulas D., Terpos E., Treatment with deferasirox (Exjade®) effectively decreases iron burden in patients with thalassaemia intermedia: results of a pilot study: correspondence. British Journal of Haematology 2010 148 2 332 334 2-s2.0-72649101965 10.1111/j.1365-2141.2009.07930.x
30. Farmakis D., Aessopos A., Pulmonary hypertension associated with hemoglobinopathies: prevalent but overlooked. Circulation 2011 123 11 1227 1232 2-s2.0-79953042691 10.1161/CIRCULATIONAHA.110.988089
31. Karimi M., Musallam K. M., Cappellini M. D., Daar S., El-Beshlawy A., Belhoul K., Saned M.-S., Temraz S., Koussa S., Taher A. T., Risk factors for pulmonary hypertension in patients with β thalassemia intermedia. European Journal of Internal Medicine 2011 22 6 607 610 2-s2.0-80855148205 10.1016/j.ejim.2011.05.013
32. Derchi G., Galanello R., Bina P., Prevalence and risk factors for pulmonary arterial hypertension in a large group of β -thalassemia patients using right heart catherization: a webthal(R) study. Circulation 2013 129 338 345 10.1161/CIRCULATIONAHA.113.002124
33. Taher A. T., Musallam K. M., Karimi M., El-Beshlawy A., Belhoul K., Daar S., Saned M., Cesaretti C., Cappellini M. D., Splenectomy and thrombosis: the case of thalassemia intermedia. Journal of Thrombosis and Haemostasis 2010 8 10 2152 2158 2-s2.0-78649339507 10.1111/j.1538-7836.2010.03940.x
34. Taher A. T., Musallam K. M., El-Beshlawy A., Karimi M., Daar S., Belhoul K., Saned M.-S., Graziadei G., Cappellini M. D., Age-related complications in treatment-naïve patients with thalassaemia intermedia. British Journal of Haematology 2010 150 4 486 489 2-s2.0-77955160429 10.1111/j.1365-2141.2010. 08220.x
35. Taher A., Isma'eel H., Cappellini M. D., Thalassemia intermedia: revisited. Blood Cells, Molecules, and Diseases 2006 37 1 12 20 2-s2.0-33745941206 10.1016/j.bcmd.2006.04.005 (Pubitemid 44062361)
36. Musallam K. M., Taher A. T., Cappellini M. D., Sankaran V. G., Clinical experience with fetal hemoglobin induction therapy in patients with β -thalassemia. Blood 2013 121 12 2199 2212